👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

Germany's Ottobock to wait until September to list amid choppy markets - sources

Published 02/18/2022, 10:28 AM
Updated 02/19/2022, 08:10 AM
© Reuters. FILE PHOTO - A bebionic hand is seen during the Ottobock media day in Vienna, Austria October 23, 2018. Picture taken October 23, 2018. REUTERS/Leonhard Foeger
GS
-
DBKGn
-
EQT
-
IVCRQ
-
BNPQY
-

(This Feb. 18 story has been refiled to fix spelling of Philipp in paragraph 13)

By Emma-Victoria Farr and Alexander Hübner

(Reuters) - German artificial limb maker Ottobock is waiting until September to launch its multibillion-euro stock market listing because of choppy financial markets, four people with knowledge of the matter said.

Many investors had expected the business, which could be valued at more than 5 billion euros ($5.7 billion), to float in the first six months of the year, after it engaged banks to prepare last summer.

Now Ottobock has decided to bide its time ahead of a listing in Frankfurt, the people said.

The company told Reuters on Friday that while it continued to prepare for a stock market listing, no final decision to do one had been taken.

"We always said that we want to be ready for the capital market from 2022," said a company spokesperson. "The preparations for this are ongoing. Whether and when we will go public has still not been decided."

European stock markets have seesawed in recent weeks as investors took fright over a potential conflict between Russia and Ukraine, as well as at the prospect of rising borrowing costs and spiralling price inflation.

A steady stream of stock-market listings had been expected in March, traditionally a busy month, but bankers have said some companies are postponing plans until later, amid growing investor uncertainty.

Ottobock, founded in 1919 as a maker of prosthesis for World War One veterans, is 80% owned by the founding Naeder family and 20% by buyout fund EQT (NYSE:EQT).

Ottobock is branching beyond medtech into industry and recently won its first industrial customer for its exoskeleton products.

Listed peers include Ossur, Hanger Invacare (NYSE:IVC) and Ekso Bionics.

The company makes prosthetics, orthotics, wheelchairs and exoskeletons and in 2019 posted core earnings of 191 million euros on sales of 1 billion euros.

While Ottobock has been considering an initial public offering (IPO) for years, EQT's stake purchase in 2017 at a valuation of 3.15 billion euros delayed earlier plans. EQT declined to comment.

Since the buyout group's investment, Ottobock named former Fresenius manager Philipp Schulte-Noelle as chief executive.

The wait until later this year will enable Ottobock to show investors a longer track-record of earnings, the people said.

© Reuters. FILE PHOTO - A bebionic hand is seen during the Ottobock media day in Vienna, Austria October 23, 2018. Picture taken October 23, 2018. REUTERS/Leonhard Foeger

Ottobock hired Deutsche Bank (DE:DBKGn), Goldman Sachs (NYSE:GS) and BNP Paribas (OTC:BNPQY) to work on IPO plans in August last year.

($1 = 0.8807 euros)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.